GERD Can Be Healed, Treatment With P-CAB Can Be A Solution

Daewoong Media Dialogue in Jakarta. (Freepic)

JAKARTA - GERD is a stomach acid disease, a chronic condition where stomach acid or other contents of the stomach rise back into the stomach (esofage). This disease is suffered by many people and can have an impact on reducing the quality of life.

However, GERD can be cured. Chairman of the Executive Board of the Indonesian Gastroenterology Association (PB PGI), Prof. Ari Fahrial Syam, said that GERD can be cured by reducing pressure on the stomach and treating ring-shaped hull or muscle clips located on the border between the concavity and the stomach.

"GERD can recover. How can we recover, the pressure on our stomach is less, the gap is tight," said Professor Ari during Daewoong Media Dialogue, in the SCBD area, Jakarta, on Thursday, August 14, 2025.

To reduce the pressure on the stomach and treat the stomach clamp, the sufferer must maintain a healthy lifestyle. Starting from avoiding foods that contain fat, controlling weight, and exercising regularly.

"By taking care of eating, chocolate, cheese, fat, you can't. If you are fat, you control your weight, you don't exercise much," he explained.

Not only that, but overcoming GERD can also be done with new generation of therapy, namely the Potassium-Competitive Acid Blocker (P-CAB). This P-CAB therapy presents three drugs, namely Fexuprazan, Vooprazan, and Tegoprazan.

These drugs provide faster work effects and last longer than the previous therapy. Eating the medicine also does not depend on eating time, it can be at any time, and is effective for 24 hours.

"In our stomach, there is a proton pump, which produces stomach acid. Well, this P-CAB blocks there, blocks it directly, is active directly," he said.

"These P-CARs work longer too, they stick longer. So they block stomach acid, and last longer," he added.

The effectiveness of P-CAB has been clinically tested on the Investigator-Initiated Trial (IIT) in the treatment of GERD initiated by Daewoong and led directly by Professor Ari.

These clinical trials show that P-CAB, in particular, the Fexuprazan provides faster symptoms of GERD, better nausea control, and improved quality of life since the first week.

"Clinical data also emphasizes a good safety profile, no serious side effects, and a high level of patient compliance thanks to a flexible one-day dose and does not depend on meal time," said Professor Ari.

As a P-CAB molecule, Fexuprazan offers a faster and more practical solution for GERD patients, especially those whose response is less than optimal with PPI-based therapy. It is hoped that in the future this innovation can be useful in Indonesian society after the testing at BPOM is carried out properly.

This study also has strategic value in strengthening the capacity of national clinical research in Indonesia. In collaboration with domestic researchers, it allows us to produce drug efficacy relevant to the Indonesian population, as well as support future data-based therapeutic decisions," concluded Daewoong Chief Medical Officer, dr. Stella Melisa.